Trial result ·
A Phase 1 clinical trial to evaluate the safety and tolerability of CLZ-2002 for the treatment of patients with Charcot-Marie-Tooth disease type 1.
Written based on 1 research study on PubMed, searched on 13 Nov 2026.
What was studied
This early-stage trial mainly checked the safety of a cell product, CLZ-2002. It was given to people with Charcot-Marie-Tooth disease type 1 (CMT1). CMT1 is an inherited nerve disease that leads to muscle loss. The cells come from donor tonsil stem cells made to act like Schwann cells. Each person got one shot into the leg muscles. Groups got a low, middle, or high dose of cells.
What they found
No harmful reactions were linked to the drug. No serious events happened, and no dose was too toxic. Some people had mild to moderate events, graded 1-2. By week 24, nerve and leg function scores had improved from the start. Blood markers NCAM1 and GDF15 dropped at week 4. By week 24, they had moved back toward starting levels.
What it means for patients
The authors say one dose was safe, even at the highest dose tested. People in the trial handled the shots well. Early tests hinted that the product may help. The authors say it should be studied in larger, controlled trials.
Why it is not certain yet
This was a Phase 1 trial in few people. There was no comparison group. Everyone knew which product they were given. The tests of benefit were only exploratory. Results are reported up to week 24. The authors call for larger, controlled studies.
Source
A Phase 1 clinical trial to evaluate the safety and tolerability of CLZ-2002 for the treatment of patients with Charcot-Marie-Tooth disease type 1.
PubMed · PMID 42522265We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Charcot-Marie-Tooth disease publications